For the Inventor, By the Inventor

Enter assignee name

Knoxville, TN, United States of America

Provectus Pharmatech, Inc

USPTO Granted Patents = 26

% Expired Patents = 34.6

CIPO Patents = 1

EPO Patents = 8

Forward Citations = 90

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Eric A Wachter (24 out of 48 patents)

H Craig Dees (13 out of 31 patents)

Timothy C Scott (11 out of 31 patents)

4. Jamie Singer (9 out of 12 patents)

5. Aru Narendran (8 out of 8 patents)

6. Dominic Rodrigues (6 out of 6 patents)

7. John T Smolik (6 out of 13 patents)

8. Satbir Thakur (5 out of 5 patents)

9. Lucy Swift (5 out of 5 patents)

10. Chunfen Zhang (5 out of 5 patents)

11. Mohit Jain (5 out of 5 patents)

12. Walter G Fisher (5 out of 17 patents)

13. Edward V Pershing (4 out of 4 patents)

14. Bruce Horowitz (4 out of 4 patents)

15. Craig J Eagle (3 out of 4 patents)

26 patents: Sort by Forward Citations

1. 12661335 - Halogenated xanthene-containing topical anti-gram-positive bacterial ophthalmic composition and method (2026-06-23),

2. 12377068 - In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors (2025-08-05),

3. 12133840 - Halogenated xanthene composition and method for treating hematologic cancers (2024-11-05),

4. 12064507 - Composition and method for oral treatment of leukemia (2024-08-20),

5. 11975106 - Uses of halogenated xanthenes in oncology and virology (2024-05-07),

6. 11974980 - In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors (2024-05-07),

7. 11938182 - Halogenated xanthenes as vaccine adjuvants (2024-03-26),

8. 11426379 - Combination of local and systemic therapies for enhanced treatment of dermatologic conditions (2022-08-30),

9. 11419844 - Halogenated xanthene composition and method for treating hematologic cancers (2022-08-23),

10. 11071781 - Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer (2021-07-27),

11. 11058664 - In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors (2021-07-13),

12. 10471144 - Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer (2019-11-12),

13. 10130658 - Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound (2018-11-20),

14. 9839688 - Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer (2017-12-12),

15. 9808524 - Combination of local and systemic immunomodulative therapies for melanoma and liver cancer (2017-11-07),

Provectus Pharmatech, Inc. is a biotechnology company specializing in the discovery and development of novel cancer therapies. With a focus on precision medicine, Provectus Pharmatech aims to improve patient outcomes and quality of life. Through comprehensive research and innovative technologies, the company develops proprietary oncology drugs that target specific cancer types and improve treatment efficacy. Utilizing advanced platforms and collaborations, Provectus Pharmatech rapidly progresses its pipeline of promising drug candidates towards clinical trials. For more information on Provectus Pharmatech and its groundbreaking cancer research, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 8 2026

26 Patents

#7 in Knoxville, TN

#126 in Tennessee

#12,828 in US

#24,711 in the World

Knoxville, TN, United States of America

Provectus Pharmatech, Inc

Forward Citations = 90

25 inventors:

Eric A Wachter (24 out of 48 patents)

H Craig Dees (13 out of 31 patents)

Timothy C Scott (11 out of 31 patents)

4. Jamie Singer (9 out of 12 patents)

5. Aru Narendran (8 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…